Navigation Links
Claimsnet.com Reports Third Quarter 2008 Results
Date:10/30/2008

Including a 27% Increase in Revenues

DALLAS, Oct. 30 /PRNewswire-FirstCall/ -- Claimsnet.com inc. (OTC Bulletin Board: CLAI), a leading provider of Internet-based claims processing solutions for the healthcare industry, today reported its results for the third quarter of 2008, which ended September 30, 2008.

"We are pleased to report a 27% increase in our third quarter revenues," commented Don Crosbie, chief executive officer of Claimsnet. "The increase in overall costs during the third quarter of 2008 was due to the addition of new clearinghouse partners as well as customer support personnel. In addition, the costs of our renewed sales effort, with the two new sales personnel added in April 2008, is reflected in the higher costs when compared to last year. However, this renewed sales effort has resulted in new payer and provider contracts and continues to build a good pipeline of opportunities. We anticipate that this renewed investment in sales growth will positively impact the financial results in the next several quarters both in sales and operating results.

For the quarter ended September 30, 2008, Claimsnet reported revenues of $527,000, a 27% increase compared to the $414,000 reported for the third quarter of 2007. Revenues for the nine months ended September 30, 2008 were $1,545,000, a 25% increase compared to the $1,240,000 reported for the nine months of 2007.

Cost of revenues for the third quarter of 2008 was $408,000 compared to $274,000 for the third quarter of 2007, a 49% increase. Cost of revenues for the nine months of 2008 was $1,218,000 compared to $846,000 for the nine months of 2007, a 44% increase. Selling, general and administrative expenses of $245,000 were reported for the third quarter of 2008 compared to $195,000 reported for the third quarter of 2007. Selling, general and administrative expenses of $732,000 were reported for the nine months of 2008 compared to $594,000 reported for the nin
'/>"/>

SOURCE Claimsnet.com inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Claimsnet.com Reports First Quarter 2008 Results
2. Claimsnet.com Reports Fiscal Year 2007 Results
3. Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need
4. Palomar Medical Reports Financial Results for Third Quarter 2008
5. Triple-S Management Corporation Reports Third Quarter 2008 Results; Board Approves Share Repurchase Authorization of up to $40 Million
6. The Quigley Corporation Reports Third Quarter 2008 Results; Continues Investment in Pharmaceutical R&D Future
7. Orchid Cellmark Reports Third Quarter 2008 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
9. Gentiva Reports Third Quarter Revenue and Profit Growth
10. LegalView Reports on Rare Traumatic Brain Injury Condition That Could Cause Complete Paralysis of A Victim
11. Uroplasty Reports Continued Progress During Second Quarter of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... on Manhattan’s Upper West Side that embodies the ... Inhabiting Eden: Christians, Scripture and the Ecological Crisis, ... A. B. Rhodes Professor Emerita of Old Testament ... Bible for ancient wisdom that lends insight into ...
(Date:9/23/2014)... benefits of preventing a reduction in the rates ... today by the American College of Physicians (ACP). ... Medicaid Primary Care Pay Parity Program: Unless Congress ... Care Will Expire," explains why it is critical ... pediatricians (and their related subspecialists), family physicians, and ...
(Date:9/23/2014)... Singapore (PRWEB) September 23, 2014 ... aesthetic clinics in Singapore and Malaysia providing advanced ... revolutionary BB powder to its impressive skin care ... strengthen the skin’s defences against the evil forces ... a healthy glow simultaneously, this new addition is ...
(Date:9/23/2014)... 2014 (HealthDay News) -- The U.S. National Institutes ... funding in scientific trials to encourage researchers to ... The supplemental monies were provided to 82 ... immunology, cardiovascular physiology, neural circuitry, and behavioral health, ... "This funding strategy demonstrates our commitment to moving ...
(Date:9/23/2014)... and a researcher in UTSA,s South Texas Center for ... Ruhr University in Bochum, Germany to understand how humans ... week in an article published by the Proceedings ... is an acute infection caused by ingestion of food ... Vibrio cholerae . An estimated three to five million ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2
... of the commonly used stimulant methylphenidate (Ritalin) to speed ... the inhaled gas isoflurane, as previously reported, and to ... Massachusetts General Hospital (MGH) research team that reported the ... the May issue of Anesthesiology, and their ...
... HealthDay Reporter , THURSDAY, April 5 (HealthDay News) -- ... crops eaten by U.S. consumers is linked to shorter ... pesticides are known as organophosphates, which kill insects by ... nerve poisons during World War II, they can disrupt ...
... Serena Gordon HealthDay Reporter , THURSDAY, April 5 ... cells that potentially grow into tumors has been one of ... researchers from the Children,s Hospital of Philadelphia have generated a ... at least for stem cells destined for the digestive system ...
... largest multicenter clinical trial of children undergoing early-stage ... management did not significantly affect neurodevelopmental outcomes at ... were innate patient characteristics and general medical morbidity ... Children born with hypoplastic left-heart syndrome (HLHS) ...
... PhD, is the 2012 recipient of Kessler Foundation,s Joel A. ... the Field of Physical Medicine & Rehabilitation (PM&R). Dr. Whyte ... in West Orange on May 10. The award includes a ... Dr. Whyte is the founding director of Moss Rehabilitation ...
... Stem Cell , a Cell Press publication, have found a ... advance in mice suggests that a combination approach to therapy ... That,s in contrast to the vast majority of CML patients ... into remission only to see their cancer return again. It ...
Cached Medicine News:Health News:Recovery from propofol anesthesia may be sped by use of common stimulant 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 2Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 3Health News:Pesticides May Be Linked to Slightly Smaller Babies, Shorter Pregnancies 4Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 2Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 3Health News:Improved Stem Cell Line May Avoid Tumor Risk: Study 4Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 2Health News:In children born with severe heart defect, surgical management has little effect on neuro outcomes 3Health News:Kessler Foundation names Dr. John Whyte recipient of Foundation's 2nd Annual DeLisa Award 2Health News:To prevent leukemia's dreaded return, go for the stem cells 2
(Date:9/23/2014)... Sept. 23, 2014 Galmed Pharmaceuticals Ltd. ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, announced today ... the FDA, approved its request for Fast Track ... treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... N.J. , Sept. 23, 2014  MEDIMETRIKS ... and William Resnick have been elected ... Mr. Lary, who will serve ... financial and investment experience to the Company.  Mr. ... Capital Advisors, LLC, a leading institutional investment firm.  ...
(Date:9/23/2014)... YORK , Sept 23, 2014  Vesselon, Inc. ... its Board of Directors, effective September 15, 2014. Dr. ... Inc. as its placement agent to market a private ... immediate and early stroke treatment. "Jurgen,s deep ... will be a great asset to Vesselon as we ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... May 16, 2011 Volcano Corporation (NASDAQ: VOLC ... Revascularization (EuroPCR) from May 17 – 20. Volcano,s focus will ... includes innovative devices like the Vascular Imaging Balloon Catheter (VIBE® ... use and value of Precision Guided Therapy in clinical practice ...
... PITTSBURGH, May 13, 2011 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has launched Cyclobenzaprine Hydrochloride (HCl) Extended-release (ER) ... first company to have filed a substantially complete ANDA ... Capsules and was awarded 180 days of marketing exclusivity. ...
Cached Medicine Technology:Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 2Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 3Volcano to Highlight its Precision Guided Therapy Technologies at EuroPCR 4
VascoScrew is a unipolar permanent pacing lead with a fixed screw a double flanch for permanent pacing. Due to latest technologies, VascoScrew D10/60 M is compatible to all pacemaker-cavities with th...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
Medicine Products: